Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Preoperative Lugol’s Solution in Graves’ Disease and Toxic Nodular Goiter
2024-517110-15-00Phase 3Authorised
- Sponsor
- Karolinska University Hospital
- Start
- Aug 2024
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label trial of Lugol's solution in hyperthyroidism, Graves' disease and Hyperfunctioning Multinodular Goiter (MNG) (2 arms), sponsored by Karolinska University Hospital. Primary endpoints: Pilot study: Response of TSH, fT4, fT3 and heart rate after iodine solution and Main study: Occurrence of postoperative temporary hypoparathyroidism. Planned start Aug 2024; status: authorised.
02
Drugs
Lugol's solution
03
Conditions
hyperthyroidismGraves' diseaseHyperfunctioning Multinodular Goiter (MNG)
Beyond the preview
Go deeper on 2024-517110-15-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-517110-15-00.